Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

China Tungsten And Hightech Ma / Index Rebalance

China Tungsten And Hightech Ma (000657 CH)

<ul>
<li>CSI confirmed 19 ADDs and 19 DELETEs for the June 2026 rebalance, effective 15 Jun 2026.</li>
<li>ADD gains narrowed to seven positive-bridge names, led by Xiamen Tungsten and China Tungsten. DELETEs fell -4.4% on average.</li>
<li>Historical first-week outcomes were negative on average for both ADD and DELETE, but different subgroup recorded varied performance.</li>
</ul>


CSI confirmed 19 ADDs and 19 DELETEs for the June 2026 rebalance, effective 15 Jun 2026.
ADD gains narrowed to seven positive-bridge names, led by Xiamen Tungsten and China Tungsten. DELETEs fell -4.4% on average.
Historical first-week outcomes were negative on average for both ADD and DELETE, but different subgroup recorded varied performance.


CSI 300 June 2026 Rebalance: Pre-Implementation Update

<ul>
<li>CSI announced 19 ADDs and 19 DELETEs effective 15 Jun 2026, the largest cycle in our four-cycle reference set.</li>
<li>We reviewed rebalance stocks against four prior CSI 300 cycles and the completed pre-announcement setup.</li>
<li>The prior forecast captured the four strongest ADDs and six of the seven weakest DELETEs, with misses mainly in buffer-zone ADDs and retained-risk DELETEs.</li>
</ul>


CSI announced 19 ADDs and 19 DELETEs effective 15 Jun 2026, the largest cycle in our four-cycle reference set.
We reviewed rebalance stocks against four prior CSI 300 cycles and the completed pre-announcement setup.
The prior forecast captured the four strongest ADDs and six of the seven weakest DELETEs, with misses mainly in buffer-zone ADDs and retained-risk DELETEs.


CSI 300 June 2026 Rebalance: Post-Announcement Positioning

Index Rebal/Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Index Rebal/Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

<ul>
<li>The ChiNext index represents 100 leading liquid stocks on the ChiNext market while the ChiNext 50 index is its subset, comprising the 50 stocks with the highest average daily turnover.</li>
<li>In this insight, we have presented our final expectations for ADDs/DELs for the upcoming index review. </li>
<li>The ChiNext and ChiNext 50 index rebal events could trigger US$981mn and US$315mn in one-way flows, respectively.</li>
</ul>


The ChiNext index represents 100 leading liquid stocks on the ChiNext market while the ChiNext 50 index is its subset, comprising the 50 stocks with the highest average daily turnover.
In this insight, we have presented our final expectations for ADDs/DELs for the upcoming index review. 
The ChiNext and ChiNext 50 index rebal events could trigger US$981mn and US$315mn in one-way flows, respectively.


Quiddity Leaderboard ChiNext & ChiNext 50 Jun26: Final Expectations; US$1bn+ Combined One-Way Flows

Verisilicon Microelectronics S / Index Rebalance

Verisilicon Microelectronics S (688521 CH)

<ul>
<li>We screened the CSI 300 eligible universe ahead of the Jun 2026 semi-annual rebalance.</li>
<li>ADDs: we expect 4 High Conviction ADDs, 6 Mid Conviction ADDs, and 3 Low Conviction ADDs.</li>
<li>We also flag 2 Skip ADDs due to CG/CSRC issues. DELETEs: we expect 8 Likely DELETEs, 3 Borderline DELETEs, 4 Rank-Driven DELETEs, and 1 Potential Retain.</li>
</ul>


We screened the CSI 300 eligible universe ahead of the Jun 2026 semi-annual rebalance.
ADDs: we expect 4 High Conviction ADDs, 6 Mid Conviction ADDs, and 3 Low Conviction ADDs.
We also flag 2 Skip ADDs due to CG/CSRC issues. DELETEs: we expect 8 Likely DELETEs, 3 Borderline DELETEs, 4 Rank-Driven DELETEs, and 1 Potential Retain.


<ul>
<li>The ChiNext index represents the 100 largest stocks in the ChiNext market and the ChiNext 50 index is its subset which includes the top 50 stocks with the highest turnover.</li>
<li>Around 91% of the reference period for the June 2026 review is now complete but rankings can still change since there are some names close to the borders.</li>
<li>We see 9 changes for the ChiNext index and 5 changes for the ChiNext 50 index during the upcoming index rebal event.</li>
</ul>


The ChiNext index represents the 100 largest stocks in the ChiNext market and the ChiNext 50 index is its subset which includes the top 50 stocks with the highest turnover.
Around 91% of the reference period for the June 2026 review is now complete but rankings can still change since there are some names close to the borders.
We see 9 changes for the ChiNext index and 5 changes for the ChiNext 50 index during the upcoming index rebal event.


Quiddity Leaderboard ChiNext & ChiNext 50 Jun26: Reference Period Ending Soon; Ranks Still Not Final

China

Pharmaron Beijing Co., Ltd. engages in discovery, development, and manufacturing spectrum for small molecule drugs, cell therapies, and gene therapies as well as providing testing services for medical devices and clinic research. The Company offers laboratory, clinical development, chemistry manufactory and control, and other services. Pharmaron Beijing conducts businesses based in China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pharmaron Beijing (300759 CH)

CSI 300 June 2026 Rebalance: Pre-Implementation Update

CSI 300 enters implementation on 15 Jun 2026. We update post-announcement stock performance and discuss implementation trades.

Ke Yan, CFA, FRM

CSI 300 June 2026 Rebalance: Post-Announcement Positioning

CSI 300 June 2026 post-announcement trading is live. ADD strength is concentrated in a few forecast names. The opening gap should set chase and...

Ke Yan, CFA, FRM

Quiddity Leaderboard ChiNext & ChiNext 50 Jun26: Final Expectations; US$1bn+ Combined One-Way Flows

The ChiNext/ChiNext 50 Jun26 index review results will be announced publicly in the next few days. In this insight, we have presented our final...

Janaghan Jeyakumar, CFA

CSI 300 May 2026 Index Review Forecast

CSI 300 May 2026 review: we expect 4 High Conviction ADDs and 6 Mid Conviction ADDs, offset by 8 Likely DELETEs, 7 Borderline or rank-driven...

Ke Yan, CFA, FRM

Quiddity Leaderboard ChiNext & ChiNext 50 Jun26: Reference Period Ending Soon; Ranks Still Not Final

Two of our ChiNext expected DELs can still escape deletion if they strongly outperform other names in the next couple of weeks. If that happens, a...

Janaghan Jeyakumar, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)